4 unknown. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
| Phase 3 | 1 | Unknown 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET Cabozantinib, Lanreotide - Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 69 | 2020-06-20 | 2021-09-05 |
| Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy Lanreotide - Acid Reflux Esophagitis, Non-acid Reflux Esophagitis | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 10 | 2014-04-01 | 2014-02-04 |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Lanreotide, Placebo (for sunitinib), Sunitinib - Carcinoid Tumors | Phase 2 | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 44 | 2013-01-07 | 2017-01-31 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
Bile Reflux (1) · Carcinoid Tumor (1) · Esophagitis, Peptic (1) · Hepatomegaly (1) · Liver Diseases (1) · Multiple Pterygium Syndrome, Autosomal Dominant (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1) · Polycystic Kidney Diseases (1) · Polycystic liver disease (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Radboud University Medical Center (1) · Universitair Ziekenhuis Brussel (1)
Belgium (3) · France (1) · Italy (1) · Netherlands (1)
Frederik Nevens, MD, PhD (1) · Joost PH Drenth, PhD (1) · Kim Moubax, Assistent (1) · Loes van Keimpema, MSc (1) · Sara Pusceddu, MD (1)
PMID 12902325, PMID 15588232, PMID 16801334, PMID 18810319, PMID 21306237, PMID 24405892, PMID 25014687, PMID 25956467, PMID 37752423
2019 (1)